Alexander H. R. Varey

Alexander H. R. Varey

Auto-generated profile, based on publicly available information

Alexander H. R. Varey

Melanoma Institute Australia, The University of Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2008 in British Journal of Cancer
Verified
Journal Article
Open access
AVA H R Varey
A H R Varey
ERE S Rennel
E S Rennel
YQY Qiu
Y Qiu
HBH S Bevan
H S Bevan
RPR M Perrin
R M Perrin
DBDave Bates
Dave Bates
Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF165 and antiangiogenic VEGF165b. Using isoform-specific enzyme-linked immunosorbent assay and quantitative polymerase chain reaction, we found that over 90% of the VEGF in normal colonic tissue was VEGFxxxb, but there was a variable upregulation of VEGFxxx and downregulation of VEGFxxxb in paired human CRC samples. Furthermore, cultured colonic adenoma cells expressed predominantly VEGFxxxb, whereas colonic carcinoma cells expressed predominantly VEGFxxx. However, adenoma cells exposed to hypoxia switched their expression from predominantly VEGFxxxb to predominantly VEGFxxx. VEGF165b overexpression in LS174t colon cancer cells inhibited colon carcinoma growth in mouse xenograft models. Western blotting and surface plasmon resonance showed that VEGF165b bound to bevacizumab with similar affinity as VEGF165. However, although bevacizumab effectively inhibited the rapid growth of colon carcinomas expressing VEGF165, it did not affect the slower growth of tumours from colonic carcinoma cells expressing VEGF165b. Both bevacizumab and anti-VEGF165b-specific antibodies were cytotoxic to colonic epithelial cells, but less so to colonic carcinoma cells. These results show that the balance of antiangiogenic to proangiogenic isoforms switches to a variable extent in CRC, regulates tumour growth rates and affects the sensitivity of tumours to bevacizumab by competitive binding. Together with the identification of an autocrine cytoprotective role for VEGF165b in colonic epithelial cells, these results indicate that bevacizumab treatment of human CRC may depend upon this balance of VEGF isoforms.

26 June 2007 in British Journal of Cancer
Verified
Journal Article
Open access
RPR O Pritchard-Jones
R O Pritchard-Jones
DDD B A Dunn
D B A Dunn
YQY Qiu
Y Qiu
AVA H R Varey
A H R Varey
AOA Orlando
A Orlando
DBDave Bates
Dave Bates
Malignant melanoma is the most lethal of the skin cancers and the UK incidence is rising faster than that of any other cancer. Angiogenesis – the growth of new vessels from preexisting vasculature – is an absolute requirement for tumour survival and progression beyond a few hundred microns in diameter. We previously described a class of anti-angiogenic isoforms of VEGF, VEGFxxxb, that inhibit tumour growth in animal models, and are downregulated in some cancers, but have not been investigated in melanoma. To determine whether VEGFxxxb expression was altered in melanoma, PCR and immunohistochemistry of archived human tumour samples were used. In normal epidermis and in a proportion of melanoma samples, VEGFxxxb staining was seen. Some melanomas had much weaker staining. Subsequent examination revealed that expression was significantly reduced in primary melanoma samples (both horizontal and vertical growth phases) from patients who subsequently developed tumour metastasis compared with those who did not (analysis of variance (ANOVA) P<0.001 metastatic vs nonmetastatic), irrespective of tumour thickness, while the surrounding epidermis showed no difference in expression. Staining for total VEGF expression showed staining in metastatic and nonmetastatic melanomas, and normal epidermis. An absence of VEGFxxxb expression appears to predict metastatic spread in patients with primary melanoma. These results suggest that there is a switch in splicing as part of the metastatic process, from anti-angiogenic to pro-angiogenic VEGF isoforms. This may form part of a wider metastatic splicing phenotype.

20 August 2014 in Molecular Oncology
Verified
Journal Article
Open access
MZMaryam A. Hamdollah Zadeh
Maryam A. Hamdollah Zadeh
EAElianna M. Amin
Elianna M. Amin
CHCoralie Hoareau-Aveilla
Coralie Hoareau-Aveilla
EDEnric Domingo
Enric Domingo
KSKirsty E. Symonds
Kirsty E. Symonds
DBDave Bates
Dave Bates
The angiogenic capability of colorectal carcinomas (CRC), and their susceptibility to anti‐angiogenic therapy, is determined by expression of vascular endothelial growth factor (VEGF) isoforms. The intracellular protein T‐cell Intracellular Antigen (TIA‐1) alters post‐transcriptional RNA processing and binds VEGF‐A mRNA. We therefore tested the hypothesis that TIA‐1 could regulate VEGF‐A isoform expression in colorectal cancers. TIA‐1 and VEGF‐A isoform expression was measured in colorectal cancers and cell lines. We discovered that an endogenous splice variant of TIA‐1 encoding a truncated protein, short TIA‐1 (sTIA‐1) was expressed in CRC tissues and invasive K‐Ras mutant colon cancer cells and tissues but not in adenoma cell lines. sTIA‐1 was more highly expressed in CRC than in normal tissues and increased with tumour stage. Knockdown of sTIA‐1 or over‐expression of full length TIA‐1 (flTIA‐1) induced expression of the anti‐angiogenic VEGF isoform VEGF‐A165b. Whereas flTIA‐1 selectively bound VEGF‐A165 mRNA and increased translation of VEGF‐A165b, sTIA‐1 prevented this binding. In nude mice, xenografted colon cancer cells over‐expressing flTIA‐1 formed smaller, less vascular tumours than those expressing sTIA‐1, but flTIA‐1 expression inhibited the effect of anti‐VEGF antibodies. These results indicate that alternative splicing of an RNA binding protein can regulate isoform specific expression of VEGF providing an added layer of complexity to the angiogenic profile of colorectal cancer and their resistance to anti‐angiogenic therapy.

10 April 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMary-Ann El Sharouni
Mary-Ann El Sharouni
TATasnia Ahmed
Tasnia Ahmed
AVAlexander H. R. Varey
Alexander H. R. Varey
SESjoerd G. Elias
Sjoerd G. Elias
AWArjen J. Witkamp
Arjen J. Witkamp
SLSerigne N. Lo
Serigne N. Lo
PURPOSE: Although the prognosis of patients with thin primary cutaneous melanomas (T1, ≤ 1.0 mm) is generally excellent, some develop recurrence. We sought to develop and validate a model predicting recurrences in patients with thin melanomas. METHODS: A Dutch population-based cohort (n = 25,930, development set) and a cohort from an Australian melanoma treatment center (n = 2,968, validation set) were analyzed (median follow-up 6.7 and 12.0 years, respectively). Multivariable Cox models were generated for local, regional, and distant recurrence-free survival (RFS). Discrimination was assessed using Harrell's C-statistic for each outcome. Each nomogram performance was evaluated using calibration plots defining low-risk and high-risk groups as the lowest and top 5% of the nomogram risk score, respectively. The nomograms' C-statistics were compared with those of a model including the current American Joint Committee on Cancer staging parameters (T-stage and sentinel node status). RESULTS: Local, regional, and distant recurrences were found in 209 (0.8%), 503 (1.9%), and 203 (0.8%) Dutch patients, respectively, and 23 (0.8%), 61 (2.1%), and 75 (2.5%) Australian patients, respectively. C-statistics of 0.79 (95% CI, 0.75 to 0.82) for local RFS, 0.77 (95% CI, 0.75 to 0.78) for regional RFS, and 0.80 (95% CI, 0.77 to 0.83) for distant RFS were obtained for the development model. External validation showed C-statistics of 0.80 (95% CI, 0.69 to 0.90), 0.76 (95% CI, 0.70 to 0.82), and 0.74 (95% CI, 0.69 to 0.80), respectively. Calibration plots showed a good match between predicted and observed rates. Using the nomogram, the C-statistic was increased by 9%-12% for the development cohort and by 11%-15% for the validation cohort, compared with a model including only T-stage and sentinel node status. CONCLUSION: Most patients with thin melanomas have an excellent prognosis, but some develop recurrence. The presented nomograms can accurately identify a subgroup at high risk. An online calculator is available at www.melanomarisk.org.au .

1 November 2017 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
AVAlexander H R Varey
Alexander H R Varey
CGChris Goumas
Chris Goumas
AHAngela M Hong
Angela M Hong
GMGraham J Mann
Graham J Mann
GFGerald B Fogarty
Gerald B Fogarty
Richard A ScolyerRichard A Scolyer
Richard A Scolyer
Neurotropic cutaneous melanoma is a rare melanoma subtype that invades nerves and is often associated with desmoplastic melanoma. Limited data suggest that it has a greater propensity to recur locally, but it is unknown whether its behavior differs from that of other melanoma subtypes, including desmoplastic melanoma. We investigated clinicopathological predictors of outcome in a cohort of 671 patients with neurotropic melanoma to develop evidence-based management recommendations. Patients with primary neurotropic melanoma diagnosed from 1985 to 2013 were identified from the Melanoma Institute Australia database, along with a control cohort of 718 non-neurotropic melanoma patients. Features predictive of sentinel lymph node status, recurrence, melanoma-specific survival and response to adjuvant radiotherapy were sought. Neither local recurrence (hazard ratio: 1.28 (0.73–2.25) P=0.39) nor melanoma-specific survival (hazard ratio: 0.79 (0.55–1.15) P=0.22) were significantly affected by the presence of neurotropism on multivariate analysis. However, there was a markedly reduced likelihood of sentinel node positivity (hazard ratio: 0.61 (0.41–0.89) P=0.01) in neurotropic melanoma patients. Surgical margins ≥8mm halved the recurrence risk compared with <2 mm margins (hazard ratio: 0.46 (0.31–0.68) P<0.001). Additionally, in neurotropic melanoma patients with <8 mm margins, adjuvant radiotherapy halved the recurrence risk (hazard ratio: 0.48 (0.27–0.87) P=0.02). This, the largest study of neurotropic melanoma reported to date, has demonstrated that the presence of neurotropism does not alter the risk of melanoma recurrence or survival but does reduce the likelihood of sentinel node positivity. For successful treatment of neurotropic melanoma, adequate excision margins are of paramount importance. However, when adequate margins cannot be achieved, adjuvant radiotherapy reduces the risk of recurrence.

25 August 2009 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
ERE S Rennel
E S Rennel
AVA H R Varey
A H R Varey
ACA J Churchill
A J Churchill
EWE R Wheatley
E R Wheatley
LSL Stewart
L Stewart
SHS J Harper
S J Harper
The key mediator of new vessel formation in cancer and other diseases is VEGF-A. VEGF-A exists as alternatively spliced isoforms - the pro-angiogenic VEGFxxx family generated by exon 8 proximal splicing, and a sister family, termed VEGFxxxb, exemplified by VEGF165b, generated by distal splicing of exon 8. However, it is unknown whether this anti-angiogenic property of VEGF165b is a general property of the VEGFxxxb family of isoforms. The mRNA and protein expression of VEGF121b was studied in human tissue. The effect of VEGF121b was analysed by saturation binding to VEGF receptors, endothelial migration, apoptosis, xenograft tumour growth, pre-retinal neovascularisation and imaging of biodistribution in tumour-bearing mice with radioactive VEGF121b. The existence of VEGF121b was confirmed in normal human tissues. VEGF121b binds both VEGF receptors with similar affinity as other VEGF isoforms, but inhibits endothelial cell migration and is cytoprotective to endothelial cells through VEGFR-2 activation. Administration of VEGF121b normalised retinal vasculature by reducing both angiogenesis and ischaemia. VEGF121b reduced the growth of xenografted human colon tumours in association with reduced microvascular density, and an intravenous bolus of VEGF121b is taken up into colon tumour xenografts. Here we identify a second member of the family, VEGF121b, with similar properties to those of VEGF165b, and underline the importance of the six amino acids of exon 8b in the anti-angiogenic activity of the VEGFxxxb isoforms.